Navigation Links
New Drug Slows Thyroid Cancer
Date:7/2/2008

Research also uncovers a genetic mutation that improves response to therapy

WEDNESDAY, July 2 (HealthDay News) -- An experimental drug that inhibits tumor blood vessel formation slows the progression of metastatic thyroid cancer in some patients, an international study finds.

Of the 93 patients with rapidly progressing cancer, 49 had a positive response to treatment with motesanib diphosphate. Of those 49 patients, 14 percent had their tumors shrink and 35 had their tumors stabilize for more than 24 weeks. Median progression-free survival was about 40 weeks.

Genetic analysis of 25 patients revealed that drug response was better in those with a mutation known as BRAF V600E in their tumors than in those without the mutation. Further research into this genetic connection is needed, the researchers said.

"Finding that patients whose tumors bear a particular mutation were more likely to respond to the drug is an example of where we would like to head in our research," study author Dr. Steven I. Sherman, chairman and professor of the department of endocrine neoplasia and hormonal disorders at the University of Texas M.D. Anderson Cancer Center, said in a prepared statement.

"This is the first of the various thyroid cancer trials to identify specific mutations that might allow us to individualize or personalize therapy," he said.

The study, published in the July 3 issue of the New England Journal of Medicine, was funded by drug maker Amgen Inc.

Motesanib diphosphate -- a VEGF inhibitor -- targets a protein called vascular endothelial growth factor (VEGF), which plays a critical role in the formation of new blood vessels that allow tumors to grow and spread.

Currently, there are few treatment options for metastatic thyroid cancer.

"There is no standard accepted chemotherapy for advanced metastatic differentiated thyroid cancer, and response rates have typically been 25 percent or less," Sherman said. "Most patients are not treated with systemic chemotherapy, because the limited benefit rarely justifies the side effects. Treatment of thyroid cancer has been a completely unmet need."

More information

The American Cancer Society has more about thyroid cancer.



-- Robert Preidt



SOURCE: University of Texas M.D. Anderson Cancer Center, news release, July 2, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Anti-Mucus Drug Slows Symptoms of COPD
2. New Compound Slows HIV Replication
3. Treating safety research like other clinical studies slows progress
4. Historic Fundraising Initiative to Empower Women & Girls Worldwide Reaches $100 Million Quickly Even as U.S. Economy Slows
5. Green Tea, Mushroom Extract Combo Slows Sarcomas
6. Diabetes Drug Slows Clogging of Arteries
7. Lithium chloride slows onset of skeletal muscle disorder
8. Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics
9. High zinc status in lung cells slows growth and induces DNA damage-induced gene expression
10. Viral Therapy Slows Pediatric Tumors in Mice
11. Targeting astrocytes slows disease progression in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Dr. ... cosmetic dental treatments to improve smiles. Cosmetic dentistry is a fast-growing field as more ... This offer allows patients to learn more about the options currently available to them ...
(Date:4/29/2016)... Grants Pass, OR (PRWEB) , ... April 29, 2016 , ... ... nutritionists suggest dinner as the meal to miss. That was among the many new ... True Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny ...
(Date:4/29/2016)... ... ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of 100 on Tampa ... for Tampa’s Best Places to Work. They were ranked in the Big Category, which ... our team,” says RMS Human Resources Manager Irene Miller. “We work hard to build ...
(Date:4/29/2016)... ... , ... Nike Softball Camp at the College of Brockport in New York ... aged 10-18. All facets of the game will be covered; hitting, fielding, base-running, and ... of the finest softball facilities in the region. The outstanding professional college staff complement ...
(Date:4/29/2016)... ... April 29, 2016 , ... HEALTHCAREfirst ... and coding services, and Deyta Analytics, recently announced the recipients of the fourth ... of quality as measured from the caregiver’s point of view. The official list ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
(Date:4/27/2016)... 2016 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends, and ... global skincare devices market was valued at US$ 7,255.8 ... a CAGR of 10.1% from 2015 to 2023 to ... the full Skincare Devices Market (Treatment Device - LED Therapy ...
(Date:4/27/2016)... NEW DELHI , April 27, 2016 ... CSR initiative to save newborns ... ,s hospital for women & newborns in collaboration with Breast ... has launched the first Pasteurized Human Milk Bank, ,Amaara, in ... the best nutritional food source for infants and should be ...
Breaking Medicine Technology: